Literature DB >> 15728379

Amphetamine induces dopamine efflux through a dopamine transporter channel.

Kristopher M Kahlig1, Francesca Binda, Habibeh Khoshbouei, Randy D Blakely, Douglas G McMahon, Jonathan A Javitch, Aurelio Galli.   

Abstract

Drugs of abuse, including cocaine, amphetamine (AMPH), and heroin, elevate extracellular dopamine (DA) levels in the brain, thereby altering the activity/plasticity of reward circuits and precipitating addiction. The physiological release of DA occurs through the calcium-dependent fusion of a synaptic vesicle with the plasma membrane. Extracellular DA is cleared by uptake through the Na+/Cl- -dependent DA transporter (DAT). In contrast, the substrate AMPH induces nonvesicular release of DA mediated by DAT. Extracellular AMPH is generally believed to trigger DA efflux through DAT by facilitating exchange for cytosolic DA. Here, in outside-out patches from heterologous cells stably expressing DAT or from dopaminergic neurons, by using ionic conditions in the patch pipette that mimic those produced by AMPH stimulation, we report that AMPH causes DAT-mediated DA efflux by two independent mechanisms: (i) a slow process consistent with an exchange mechanism and (ii) a process that results in rapid (millisecond) bursts of DA efflux through a channel-like mode of DAT. Because channel-like release of DA induced by AMPH is rapid and contains a large number of DA molecules, with a single burst of DA on par with a quantum of DA from exocytotic release of a vesicle, this burst mode of release may play a role in the synaptic actions and psychostimulant properties of AMPH and related compounds. Unlike AMPH, the endogenous substrate DA, when present on both sides of the plasma membrane, inhibits this channel-like activity, thereby suggesting that the DAT channel-like mode cannot accumulate DA against a concentration gradient.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15728379      PMCID: PMC549289          DOI: 10.1073/pnas.0407737102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

Review 1.  Regulation of quantal size by presynaptic mechanisms.

Authors:  D Sulzer; E N Pothos
Journal:  Rev Neurosci       Date:  2000       Impact factor: 4.353

2.  From a pump to a pore: how palytoxin opens the gates.

Authors:  Donald W Hilgemann
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-13       Impact factor: 11.205

Review 3.  Plasma membrane monoamine transporters: structure, regulation and function.

Authors:  Gonzalo E Torres; Raul R Gainetdinov; Marc G Caron
Journal:  Nat Rev Neurosci       Date:  2003-01       Impact factor: 34.870

4.  Macrophage scavenger receptor confers an adherent phenotype to cells in culture.

Authors:  A K Robbins; R A Horlick
Journal:  Biotechniques       Date:  1998-08       Impact factor: 1.993

5.  Patch-clamp and amperometric recordings from norepinephrine transporters: channel activity and voltage-dependent uptake.

Authors:  A Galli; R D Blakely; L J DeFelice
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

6.  A regulated interaction of syntaxin 1A with the antidepressant-sensitive norepinephrine transporter establishes catecholamine clearance capacity.

Authors:  Uhna Sung; Subramaniam Apparsundaram; Aurelio Galli; Kristopher M Kahlig; Valentina Savchenko; Sally Schroeter; Michael W Quick; Randy D Blakely
Journal:  J Neurosci       Date:  2003-03-01       Impact factor: 6.167

7.  Dendrodendritic inhibition through reversal of dopamine transport.

Authors:  B H Falkenburger; K L Barstow; I M Mintz
Journal:  Science       Date:  2001-09-28       Impact factor: 47.728

8.  Dopamine transporters depolarize neurons by a channel mechanism.

Authors:  Lucia Carvelli; Paul W McDonald; Randy D Blakely; Louis J DeFelice
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-01       Impact factor: 11.205

9.  Cocaine alters the accessibility of endogenous cysteines in putative extracellular and intracellular loops of the human dopamine transporter.

Authors:  J V Ferrer; J A Javitch
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

10.  Dopamine transporter-mediated conductances increase excitability of midbrain dopamine neurons.

Authors:  Susan L Ingram; Balakrishna M Prasad; Susan G Amara
Journal:  Nat Neurosci       Date:  2002-10       Impact factor: 24.884

View more
  112 in total

Review 1.  The solute carrier 6 family of transporters.

Authors:  Stefan Bröer; Ulrik Gether
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

2.  Dysregulation of dopamine transporters via dopamine D2 autoreceptors triggers anomalous dopamine efflux associated with attention-deficit hyperactivity disorder.

Authors:  Erica Bowton; Christine Saunders; Kevin Erreger; Dhananjay Sakrikar; Heinrich J Matthies; Namita Sen; Tammy Jessen; Roger J Colbran; Marc G Caron; Jonathan A Javitch; Randy D Blakely; Aurelio Galli
Journal:  J Neurosci       Date:  2010-04-28       Impact factor: 6.167

3.  Dopamine D(3) receptors contribute to methamphetamine-induced alterations in dopaminergic neuronal function: role of hyperthermia.

Authors:  Michelle G Baladi; Amy H Newman; Shannon M Nielsen; Glen R Hanson; Annette E Fleckenstein
Journal:  Eur J Pharmacol       Date:  2014-03-28       Impact factor: 4.432

4.  The primate thalamus is a key target for brain dopamine.

Authors:  Miguel Angel Sánchez-González; Miguel Angel García-Cabezas; Beatriz Rico; Carmen Cavada
Journal:  J Neurosci       Date:  2005-06-29       Impact factor: 6.167

5.  Nonvesicular inhibitory neurotransmission via reversal of the GABA transporter GAT-1.

Authors:  Yuanming Wu; Wengang Wang; Ana Díez-Sampedro; George B Richerson
Journal:  Neuron       Date:  2007-12-06       Impact factor: 17.173

Review 6.  Bath salts and synthetic cathinones: an emerging designer drug phenomenon.

Authors:  Christopher L German; Annette E Fleckenstein; Glen R Hanson
Journal:  Life Sci       Date:  2013-08-02       Impact factor: 5.037

7.  A case of amelioration of venlafaxine-discontinuation "brain shivers" with atomoxetine.

Authors:  Jose A Cortes; Rajiv Radhakrishnan
Journal:  Prim Care Companion CNS Disord       Date:  2013

8.  Dopaminergic and cholinergic modulation of striatal tyrosine hydroxylase interneurons.

Authors:  Osvaldo Ibáñez-Sandoval; Harry S Xenias; James M Tepper; Tibor Koós
Journal:  Neuropharmacology       Date:  2015-04-20       Impact factor: 5.250

Review 9.  The dopamine transporter: An unrecognized nexus for dysfunctional peripheral immunity and signaling in Parkinson's Disease.

Authors:  Phillip Mackie; Joe Lebowitz; Leila Saadatpour; Emily Nickoloff; Peter Gaskill; Habibeh Khoshbouei
Journal:  Brain Behav Immun       Date:  2018-03-15       Impact factor: 7.217

Review 10.  Behavioral genetic contributions to the study of addiction-related amphetamine effects.

Authors:  Tamara J Phillips; Helen M Kamens; Jeanna M Wheeler
Journal:  Neurosci Biobehav Rev       Date:  2007-11-29       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.